E.U. Delays Vote on Roundup

Newly published research on the key ingredient in the Monsanto-made weed killer is holding up lawmakers’ decisions on whether to continue to allow its sale in Europe.

Written byBob Grant
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, NIGEL MYKURAThe United Nations and the World Health Organization (WHO) agree that the active ingredient in Monsanto’s Roundup herbicide is “unlikely to pose a carcinogenic risk to humans from exposure through the diet.” The recently released, joint report seems to contradict 2015 WHO glyphosate research, which concluded that the chemical was “probably carcinogenic to humans.” The confusion is delaying a European Union (E.U.) vote on whether to renew the sales authorization of glyphosate. That vote was postponed on May 19, and the current sales license for Roundup expires on June 30. Several E.U. member states, including France and Germany called for delaying the vote until the confusion is cleared up.

“Safety first, health first. I am against authorizing this product until these doubts have been entirely ruled out,” Sigmar Gabriel, Germany's vice chancellor told The Wall Street Journal.

The WHO, for its part, tried to clear up the seemingly conflicting assessments of glyphosate, claiming in a FAQ that the new report and the 2015 report are “different, yet complimentary” because the earlier one did not estimate risk based on feasible exposure routes. Other assessments, including one from the European Food Safety Authority, have supported the claim that glyphosate is unlikely to cause cancer in human populations.

Update (July 1): The European Commission announced this week (June 28) that it is temporarily granting farmers in the European Union clearance to use glyphosate through 2017. The temporary ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies